Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

36 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Third-Party and Patient-Specific Donor-Derived Virus-Specific T Cells Demonstrate Similar Efficacy and Safety for Management of Viral Infections after Hematopoietic Stem Cell Transplantation in Children and Young Adults.
Galletta TJ, Lane A, Lutzko C, Leemhuis T, Cancelas JA, Khoury R, Wang YM, Hanley PJ, Keller MD, Bollard CM, Davies SM, Grimley MS, Rubinstein JD. Galletta TJ, et al. Among authors: rubinstein jd. Transplant Cell Ther. 2023 May;29(5):305-310. doi: 10.1016/j.jtct.2023.01.027. Epub 2023 Feb 3. Transplant Cell Ther. 2023. PMID: 36736781 Free article.
Virus-specific T-cell therapy to treat BK polyomavirus infection in bone marrow and solid organ transplant recipients.
Nelson AS, Heyenbruch D, Rubinstein JD, Sabulski A, Jodele S, Thomas S, Lutzko C, Zhu X, Leemhuis T, Cancelas JA, Keller M, Bollard CM, Hanley PJ, Davies SM, Grimley MS. Nelson AS, et al. Among authors: rubinstein jd. Blood Adv. 2020 Nov 24;4(22):5745-5754. doi: 10.1182/bloodadvances.2020003073. Blood Adv. 2020. PMID: 33216887 Free PMC article. Clinical Trial.
Virus-specific T cells for adenovirus infection after stem cell transplantation are highly effective and class II HLA restricted.
Rubinstein JD, Zhu X, Leemhuis T, Pham G, Ray L, Emberesh S, Jodele S, Thomas S, Cancelas JA, Bollard CM, Hanley PJ, Keller MD, Grimley O, Clark D, Clark T, Lindestam Arlehamn CS, Sette A, Davies SM, Nelson AS, Grimley MS, Lutzko C. Rubinstein JD, et al. Blood Adv. 2021 Sep 14;5(17):3309-3321. doi: 10.1182/bloodadvances.2021004456. Blood Adv. 2021. PMID: 34473237 Free PMC article. Clinical Trial.
Off-the-Shelf Third-Party Virus-Specific T Cell Therapy to Treat JC Polyomavirus Infection in Hematopoietic Stem Cell Transplantation Recipients.
Rubinstein JD, Jodele S, Heyenbruch D, Wilhelm J, Thomas S, Lutzko C, Zhu X, Leemhuis T, Cancelas JA, Keller M, Bollard CM, Hanley PJ, Boghdadly ZE, Mims A, Davies SM, Grimley MS, Nelson AS. Rubinstein JD, et al. Transplant Cell Ther. 2022 Feb;28(2):116.e1-116.e7. doi: 10.1016/j.jtct.2021.11.005. Epub 2021 Nov 14. Transplant Cell Ther. 2022. PMID: 34785398 Free article.
Scheduled administration of virus-specific T cells for viral prophylaxis after pediatric allogeneic stem cell transplant.
Rubinstein JD, Lutzko C, Leemhuis T, Zhu X, Pham G, Ray L, Thomas S, Dourson C, Wilhelm J, Lane A, Cancelas JA, Lipps D, Ferrell J, Hanley PJ, Keller MD, Bollard CM, Wang YM, Davies SM, Nelson AS, Grimley MS. Rubinstein JD, et al. Blood Adv. 2022 May 10;6(9):2897-2907. doi: 10.1182/bloodadvances.2021006309. Blood Adv. 2022. PMID: 35108727 Free PMC article. Clinical Trial.
36 results